Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’

RNAi specialist Alnylam Pharmaceuticals will advance the Huntington’s disease drug brezosiran into a placebo-controlled study in 2027 once regulatory alignment is achieved.